A lack of fast, reliable diagnostic testing has played a major role in the rapid proliferation of cases of COVID-19. Rahul Dhanda ’95 and his team at Sherlock Biosciences are working furiously to change that, potentially shortening the testing’s time horizon to a matter of minutes. Dhanda is co-founder, CEO, and president of the engineering biology startup based in Cambridge, Mass., which is creating two different diagnostic tests for COVID-19—one rooted in CRISPR technology, the other in synthetic biology. The hope is that the tests can be released during the course of the current pandemic, Dhanda said, each with its…